Metrics to compare | 203400 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship203400PeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.5x | −16.3x | −0.5x | |
PEG Ratio | −0.17 | −0.28 | 0.00 | |
Price/Book | 3.6x | 3.6x | 2.6x | |
Price / LTM Sales | 280.5x | 26.6x | 3.2x | |
Upside (Analyst Target) | - | 242.4% | 48.1% | |
Fair Value Upside | Unlock | −1.6% | 6.6% | Unlock |
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.